2020

MAIT cell subtypes in multiple sclerosis.

Ammitzbøll C, von Essen MR, Chow HH, McWilliam O, Holm Hansen R, Sellebjerg F. J Neuroimmunol. 2020 Feb 15;339:577117. 

Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.

Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Neurology. 2020 May 5;94(18):e1950-e1960.

Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis.

Holm Hansen R, Højsgaard Chow H, Christensen JR, Sellebjerg F, von Essen MR. Mult Scler Relat Disord. 2020 Jan;37:101451.

Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.

Sellebjerg F, Blinkenberg M, Sorensen PS. CNS Drugs. 2020 Mar;34(3):269-280. 

Serum neurofilament light as a biomarker in progressive multiple sclerosis.

Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, Furlan R, Harp C, Kuhle J, Leppert D, Plavina T, Sellebjerg F, Sincock C, Teunissen CE, Topalli I, von Raison F, Walker E, Fox RJ. Neurology. 2020 Sep 8;95(10):436-444. 

Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease.

von Essen MR, Hellem MNN, Vinther-Jensen T, Ammitzbøll C, Hansen RH, Hjermind LE, Nielsen TT, Nielsen JE, Sellebjerg F. Ann Neurol. 2020 Feb;87(2):246-255. 

Aggressive multiple sclerosis (1): Towards a definition of the phenotype.

Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L; 2018 ECTRIMS Focused Workshop Group. Mult Scler. 2020 Jun 12;26(9):1352458520925369.

Aggressive multiple sclerosis (2): Treatment.

Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018 ECTRIMS Focused Workshop Group. Mult Scler. 2020 Jun 12;26(9):1352458520924595.

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.

Sorensen PS, Sellebjerg F, Hartung HP, Montalban X, Comi G, Tintoré M. Brain. 2020 Sep 1;143(9):2637-2652. 

Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.

Marstrand L, Østerberg O, Walsted T, Skov AC, Schreiber KI, Sellebjerg F. Mult Scler Relat Disord. 2020 Jan;37:101458.

Serum neurofilament light chain in healthy elderly and in patients with age-related macular degeneration.

Krogh Nielsen M, Subhi Y, Rue Molbech C, Sellebjerg F, Sørensen TL. Acta Ophthalmol. 2020 May;98(3):e393-e394. 

Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.

Papp V, Petersen T, Magyari M, Koch-Henriksen N, Frederiksen JL, Sellebjerg F, Stenager E, Illes Z. Neurology. 2020 Jun 9;94(23):1048-1049.

Biomarkers of inflammation and epithelial barrier function in multiple sclerosis.

Olsson A, Gustavsen S, Hasselbalch IC, Langkilde AR, Sellebjerg F, Oturai AB, Søndergaard HB. Mult Scler Relat Disord. 2020 Sep 19;46:102520. 

Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.

Mahler MR, Søndergaard HB, Buhelt S, von Essen MR, Romme Christensen J, Enevold C, Sellebjerg F. Mult Scler Relat Disord. 2020 Oct;45:102391.

Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.

Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Christensen JR, Christensen MK, Hansen V, Illes Z, Jensen HB, Kant M, Papp V, Petersen T, Rasmussen PV, Schäfer J, Theódórsdóttir Á, Weglewski A, Sorensen PS, Magyari M. Neurology. 2020 Aug 25;95(8):e1041-e1051. 

Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.

Oturai DB, Bach Søndergaard H, Koch-Henriksen N, Andersen C, Laursen JH, Gustavsen S, Kristensen JT, Magyari M, Sørensen PS, Sellebjerg F, Thørner LW, Ullum H, Oturai AB. Mult Scler. 2020 Mar 23:1352458520912500. 

Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis.

Andersen KW, Lasič S, Lundell H, Nilsson M, Topgaard D, Sellebjerg F, Szczepankiewicz F, Siebner HR, Blinkenberg M, Dyrby TB. Brain Commun. 2020 Jun 8;2(2):fcaa077. 

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

Andlauer TFM, Link J, Martin D, Ryner M, Hermanrud C, Grummel V, Auer M, Hegen H, Aly L, Gasperi C, Knier B, Müller-Myhsok B, Jensen PEH, Sellebjerg F, Kockum I, Olsson T, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, Hemmer B; ABIRISK consortium. BMC Med. 2020 Nov 4;18(1):298. 

Motor fatigue is associated with asymmetric connectivity properties of the corticospinal tract in multiple sclerosis.

Bauer C, Dyrby TB, Sellebjerg F, Madsen KS, Svolgaard O, Blinkenberg M, Siebner HR, Andersen KW. Neuroimage Clin. 2020 Aug 25;28:102393.

Corrigendum to "Brief international cognitive assessment for multiple sclerosis (BICAMS): A Danish validation study of sensitivity in early stages of MS" 

Marstrand L, Østerberg O, Walsted T, Skov AC, Schreiber KI, Sellebjerg F. Mult Scler Relat Disord. 2020 Feb;38:101942. 

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.

Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, Wuerfel J, Sormani MP, Barkhof F, Yousry TA, De Stefano N, Tintoré M, Filippi M, Gasperini C, Kappos L, Río J, Frederiksen J, Palace J, Vrenken H, Montalban X, Rovira À; MAGNIMS study group. Nat Rev Neurol. 2020 Mar;16(3):171-182.

Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.

de Sitter A, Visser M, Brouwer I, Cover KS, van Schijndel RA, Eijgelaar RS, Müller DMJ, Ropele S, Kappos L, Rovira Á, Filippi M, Enzinger C, Frederiksen J, Ciccarelli O, Guttmann CRG, Wattjes MP, Witte MG, de Witt Hamer PC, Barkhof F, Vrenken H; MAGNIMS Study Group and Alzheimer’s Disease Neuroimaging Initiative. Eur Radiol. 2020 Feb;30(2):1062-1074. 

Comorbidity in Multiple Sclerosis.

Magyari M, Sorensen PS. Front Neurol. 2020 Aug 21;11:851. 

Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study.

Ibfelt EH, Jacobsen RK, Kopp TI, Cordtz RL, Jakobsen AS, Seersholm N, Shaker SB, Dreyer L. Rheumatology (Oxford). 2020 Aug 11:327.

COVID-19 in people with multiple sclerosis: A global data sharing initiative.

Peeters LM, Parciak T, Walton C, Geys L, Moreau Y, De Brouwer E, Raimondi D, Pirmani A, Kalincik T, Edan G, Simpson-Yap S, De Raedt L, Dauxais Y, Gautrais C, Rodrigues PR, McKenna L, Lazovski N, Hillert J, Forsberg L, Spelman T, McBurney R, Schmidt H, Bergmann A, Braune S, Stahmann A, Middleton R, Salter A, Bebo BF, Rojas JI, van der Walt A, Butzkueven H, van der Mei I, Ivanov R, Hellwig K, Sciascia do Olival G, Cohen JA, Van Hecke W, Dobson R, Magyari M, Brum DG, Alonso R, Nicholas R, Bauer J, Chertcoff A, de Sèze J, Louapre C, Comi G, Rijke N. Mult Scler. 2020 Sep;26(10):1157-1162. 

Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.

Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Christensen JR, Christensen MK, Hansen V, Illes Z, Jensen HB, Kant M, Papp V, Petersen T, Rasmussen PV, Schäfer J, Theódórsdóttir Á, Weglewski A, Sorensen PS, Magyari M. Neurology. 2020 Aug 25;95(8):e1041-e1051.

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.

Dalla Costa G, Leocani L, Montalban X, Guerrero AI, Sørensen PS, Magyari M, Dobson RJB, Cummins N, Narayan VA, Hotopf M, Comi G; RADAR-CNS consortium. Neurol Sci. 2020 Jul;41(7):1647-1650. 

Pharmacotherapeutic considerations in women with multiple sclerosis.

Andersen JB, Magyari M. Expert Opin Pharmacother. 2020 Sep;21(13):1591-1602

Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.

Papp V, Petersen T, Magyari M, Koch-Henriksen N, Frederiksen JL, Sellebjerg F, Stenager E, Illes Z. Neurology. 2020 Jun 9;94(23):1048-1049. 

Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.

Oturai DB, Bach Søndergaard H, Koch-Henriksen N, Andersen C, Laursen JH, Gustavsen S, Kristensen JT, Magyari M, Sørensen PS, Sellebjerg F, Thørner LW, Ullum H, Oturai AB. Mult Scler. 2020 Mar 23:1352458520912500. 

Associations between common polymorphisms in CYP2R1 and GC, Vitamin D intake and risk of colorectal cancer in a prospective case-cohort study in Danes.

Kopp TI, Vogel U, Andersen V. PLoS One. 2020 Feb 3;15(2):e0228635. 

Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.

Kopp TI, Blinkenberg M, Petersen T, Sorensen PS, Magyari M. Mult Scler Relat Disord. 2020 May;40:101956. 

School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.

Boesen MS, Blinkenberg M, Thygesen LC, Eriksson F, Magyari M. Mult Scler. 2020 Sep 25:1352458520959673. 

Intake of dietary fibre, red and processed meat and risk of late-onset Chronic Inflammatory Diseases: A prospective Danish study on the "diet, cancer and health" cohort.

Rubin KH, Rasmussen NF, Petersen I, Kopp TI, Stenager E, Magyari M, Hetland ML, Bygum A, Glintborg B, Andersen V. Int J Med Sci. 2020 Sep 9;17(16):2487-2495.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C. Mult Scler. 2020 Jul;26(8):912-923. 

Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases.

Passali M, Josefsen K, Frederiksen JL, Antvorskov JC. Nutrients. 2020 Aug 1;12(8):2316. 

Functional-structural assessment of the optic pathways in patients with optic neuritis.

Schmidt MF, Pihl-Jensen G, Frederiksen JL. Doc Ophthalmol. 2020 Apr;140(2):159-168. 

Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test.

Pihl-Jensen G, Ivanov I, Hinze D, Trauzettel-Klosinski S, Frederiksen JL. Ophthalmic Res. 2020;63(3):332-340. 

Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis.

Mailand MT, Frederiksen JL. Mol Diagn Ther. 2020 Jun;24(3):263-277.

Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis.

Ahmad U, Frederiksen JL. Mult Scler Relat Disord. 2020 Sep 18;46:102509. 

Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis.

Houen G, Heiden J, Trier NH, Draborg AH, Benros ME, Zinkevičiūtė R, Petraitytė-Burneikienė R, Ciplys E, Slibinskas R, Frederiksen JL. J Neuroimmunol. 2020 Jul 7;346:577314.

Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

Olesen MN, Nilsson AC, Pihl-Jensen G, Soelberg KK, Olsen DA, Brandslund I, Lillevang ST, Madsen JS, Frederiksen JL, Asgari N. Mult Scler Relat Disord. 2020 Jun 11;44:102281. 

Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.

Pihl-Jensen G, Wanscher B, Frederiksen JL. Mult Scler. 2020 Jun 8:1352458520917924. 

Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.

de Sitter A, Verhoeven T, Burggraaff J, Liu Y, Simoes J, Ruggieri S, Palotai M, Brouwer I, Versteeg A, Wottschel V, Ropele S, Rocca MA, Gasperini C, Gallo A, Yiannakas MC, Rovira A, Enzinger C, Filippi M, De Stefano N, Kappos L, Frederiksen JL, Uitdehaag BMJ, Barkhof F, Guttmann CRG, Vrenken H; MAGNIMS Study Group. J Neurol. 2020 Dec;267(12):3541-3554. 

A novel neurodegenerative spectrum disorder in patients with MLKL deficiency.

Faergeman SL, Evans H, Attfield KE, Desel C, Kuttikkatte SB, Sommerlund M, Jensen LT, Frokiaer J, Friese MA, Matthews PM, Luchtenborg C, Brügger B, Oturai AB, Dendrou CA, Fugger L. Cell Death Dis. 2020 May 1;11(5):303. 

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.

Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P; ABIRISK consortium. PLoS Med. 2020 Oct 30;17(10):e1003348. 

Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.

Jonsson DI, Sveinsson O, Hakim R, Brundin L. Neurology. 2019 Jul 9;93(2):e181-e189. 

Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis.

Noory N, Smilkov EA, Frederiksen JL, Heinskou TB, Andersen ASS, Bendtsen L, Maarbjerg S. Cephalalgia. 2020 Nov 28:333102420974356.

  2019

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.

International Multiple Sclerosis Genetics Consortium. Science. 2019 Sep 27;365(6460):7188. 

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.

Holm Hansen R, Højsgaard Chow H, Sellebjerg F, Rode von Essen M. Mult Scler. 2019 Aug;25(9):1289-1297. 

Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.

von Essen MR, Ammitzbøll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, Damm P, Sellebjerg F. Brain. 2019 Jan 1;142(1):120-132. 

Pulsed immune reconstitution therapy in multiple sclerosis.

Sorensen PS, Sellebjerg F. Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913. 

The Multiple Sclerosis Care Unit.

Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G. Mult Scler. 2019 Apr;25(5):627-636.

IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis.

von Essen MR, Søndergaard HB, Petersen ERS, Sellebjerg F. Cells. 2019 Mar 26;8(3):285. 

Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.

Sellebjerg F, Royen L, Soelberg Sørensen P, Oturai AB, Jensen PEH. Mult Scler. 2019 Oct;25(11):1444-1451. 

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.

Petersen ER, Søndergaard HB, Laursen JH, Olsson AG, Börnsen L, Soelberg Sørensen P, Sellebjerg F, Bang Oturai A. Mult Scler. 2019 Aug;25(9):1298-1305. 

Multiple sclerosis and cancer incidence: A Danish nationwide cohort study.

Nørgaard M, Veres K, Didden EM, Wormser D, Magyari M. Mult Scler Relat Disord. 2019 Feb;28:81-85. 

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.

Holm Hansen R, Højsgaard Chow H, Sellebjerg F, Rode von Essen M. Mult Scler. 2019 Aug;25(9):1289-1297. 

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Mult Scler Relat Disord. 2019 Jan;27:171-178. 

GPR15⁺ T cells are Th17 like, increased in smokers and associated with multiple sclerosis.

Ammitzbøll C, von Essen MR, Börnsen L, Petersen ER, McWilliam O, Ratzer R, Romme Christensen J, Oturai AB, Søndergaard HB, Sellebjerg F. J Autoimmun. 2019 Feb;97:114-121. 

Prediction of natalizumab anti-drug antibodies persistency.

Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, Sievers C, Lindberg R, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium. Mult Scler. 2019 Mar;25(3):392-398. 

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, Sellebjerg F. Mult Scler. 2019 Jun;25(7):937-946. 

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.

Chalmer TA, Kalincik T, Laursen B, Sorensen PS, Magyari M; Members of Danish Multiple Sclerosis Group. J Neurol. 2019 Feb;266(2):306-315. 

Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.

Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M. Neurology. 2019 Apr 16;92(16):e1811-e1820.

Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.

Boesen MS, Koch-Henriksen N, Thygesen LC, Eriksson F, Greisen G, Born AP, Blinkenberg M, Uldall PV, Magyari M. Mult Scler. 2019 May;25(6):783-791.

Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients.

Arngrim N, Hougaard A, Schytz HW, Vestergaard MB, Britze J, Amin FM, Olsen KS, Larsson HB, Olesen J, Ashina M. J Cereb Blood Flow Metab. 2019 Apr;39(4):680-689.

Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.

Andersen C, Søndergaard HB, Bang Oturai D, Laursen JH, Gustavsen S, Larsen NK, Magyari M, Just-Østergaard E, Thørner LW, Sellebjerg F, Ullum H, Oturai AB. Mult Scler. 2019 Oct;25(12):1572-1579.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ. JAMA Neurol. 2019 Jun 17;76(9):1035-48.

  2018

Progressive multiple sclerosis, cognitive function, and quality of life.

Højsgaard Chow H, Schreiber K, Magyari M, Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Soelberg Sørensen P, Sellebjerg F. Brain Behav. 2018 Jan 5;8(2):e00875. 

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Lancet Neurol. 2018 Feb;17(2):162-173. 

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS. Neurology. 2018 May 15;90(20):e1805-e1814. 

Optical coherence tomography in multiple sclerosis.

Britze J, Frederiksen JL. Eye (Lond). 2018 May;32(5):884-888.

Early versus later treatment start in multiple sclerosis: a register-based cohort study.

Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group. Eur J Neurol. 2018 Oct;25(10):1262-e110. 

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.

Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G. Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617753365. 

B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response.

McWilliam O, Sellebjerg F, Marquart HV, von Essen MR. J Neuroimmunol. 2018 Nov 15;324:157-164. 

The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis.

Hasselbalch IC, Søndergaard HB, Koch-Henriksen N, Olsson A, Ullum H, Sellebjerg F, Oturai AB. Mult Scler J Exp Transl Clin. 2018 Nov 28;4(4):2055217318813183. 

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium. Cell. 2018 Nov 29;175(6):1679-1687.e7. 

Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Martin NA, Nawrocki A, Molnar V, Elkjaer ML, Thygesen EK, Palkovits M, Acs P, Sejbaek T, Nielsen HH, Hegedus Z, Sellebjerg F, Molnar T, Barbosa EGV, Alcaraz N, Gallyas F Jr, Svenningsen AF, Baumbach J, Lassmann H, Larsen MR, Illes Z. PLoS One. 2018 Aug 16;13(8):e0202530.

Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study.

Boesen MS, Thygesen LC, Uldall PV, Eriksson F, Born AP, Blinkenberg M, Koch-Henriksen N, Greisen G, Magyari M. Mult Scler Relat Disord. 2018 Jan;19:30-34. 

Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.

Boesen MS, Magyari M, Koch-Henriksen N, Thygesen LC, Born AP, Uldall PV, Blinkenberg M. Mult Scler. 2018 Jul;24(8):1077-1086.

Male factor infertility and risk of multiple sclerosis: A register-based cohort study.

Glazer CH, Tøttenborg SS, Giwercman A, Bräuner EV, Eisenberg ML, Vassard D, Magyari M, Pinborg A, Schmidt L, Bonde JP. Mult Scler. 2018 Dec;24(14):1835-1842. 

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group. Mult Scler. 2018 Apr 1;24(5):590-603. 

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F. Mult Scler Relat Disord. 2018 Feb;20:73-77.

Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study.

Andersen JB, Moberg JY, Spelman T, Magyari M. Front Immunol. 2018 Nov 23;9:2706.

Small-scale geographical variation in multiple sclerosis: A case-control study using Danish register data 1971-2013.

Bihrmann K, Nielsen NM, Magyari M, Koch-Henriksen N, Nordsborg RB, Ersbøll AK. Mult Scler Relat Disord. 2018 Jul;23:40-45.

Implications of the International Paediatric Multiple Sclerosis Study Group consensus criteria for paediatric acute disseminated encephalomyelitis: a nationwide validation study.

Boesen MS, Blinkenberg M, Koch-Henriksen N, Thygesen LC, Uldall PV, Magyari M, Born AP. Dev Med Child Neurol. 2018 Nov;60(11):1123-1131.

Pediatric acquired demyelinating syndromes: a nationwide validation study of the Danish National Patient Register.

Boesen MS, Magyari M, Born AP, Thygesen LC. Clin Epidemiol. 2018 Apr 10;10:391-399. 

Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.

Boesen MS, Jensen PEH, Magyari M, Born AP, Uldall PV, Blinkenberg M, Sellebjerg F. Mult Scler Relat Disord. 2018 Aug;24:175-183.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. Eur J Neurol. 2018 May;25(5):739-746.

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Mult Scler. 2018 Oct;24(12):1594-1604. 

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Lancet Neurol. 2018 May;17(5):405-415. 

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Mult Scler. 2018 Feb;24(2):96-120. 

Bone microarchitecture and bone mineral density in multiple sclerosis.

Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS. Acta Neurol Scand. 2018 Mar;137(3):363-369. 

Clinical utility of anti-MOG antibody testing in a Danish cohort.

Papp V, Langkilde AR, Blinkenberg M, Schreiber K, Jensen PEH, Sellebjerg F. Mult Scler Relat Disord. 2018 Nov;26:61-67. 

Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.

Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, Roemer SF, Jensen MB, Petersen AE, Nielsen HH, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen PE, Lydolph MC, Heegaard N, Frederiksen JL, Sellebjerg F, Stenager E, Petersen T. Neurology. 2018 Dec 11;91(24):e2265-e2275. 

Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013.

Pedersen EG, Hallas J, Pottegård A, Hald SM, Jensen PEH, Gaist D. Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):486-493. 

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB. Neurology. 2018 Feb 13;90(7):e593-e600. 

Inflammatory markers of CHMP2B-mediated frontotemporal dementia.

Roos P, von Essen MR, Nielsen TT, Johannsen P, Stokholm J, Bie AS, Waldemar G, Simonsen AH, Heslegrave A, Zetterberg H; FReJA consortium, Sellebjerg F, Nielsen JE. J Neuroimmunol. 2018 Nov 15;324:136-142. 

Male factor infertility and risk of multiple sclerosis: A register-based cohort study.

Glazer CH, Tøttenborg SS, Giwercman A, Bräuner EV, Eisenberg ML, Vassard D, Magyari M, Pinborg A, Schmidt L, Bonde JP. Mult Scler. 2018 Dec;24(14):1835-1842.

Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.

Rasmussen PV, Magyari M, Moberg JY, Bøgelund M, Jensen UFA, Madsen KG. Mult Scler Relat Disord. 2018 Aug;24:129-134. 

High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study.

Schreiber K, Kant M, Pfleger C, Jensen HB, Oesterberg O, Hald AR, Nielsen FK, Rubak S. Patient Prefer Adherence. 2018 Jun 29;12:1139-1150.

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.

De Stefano N, Giorgio A, Tintoré M, Pia Amato M, Kappos L, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group. Mult Scler. 2018 Feb;24(2):214-221. 

Cerebellar and premotor activity during a non-fatiguing grip task reflects motor fatigue in relapsing-remitting multiple sclerosis.

Svolgaard O, Andersen KW, Bauer C, Madsen KH, Blinkenberg M, Selleberg F, Siebner HR. PLoS One. 2018 Oct 24;13(10):e0201162.

  2017

Smoking reduces circulating CD26^hiCD161^hi MAIT cells in healthy individuals and patients with multiple sclerosis.

Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Romme Nielsen B, Søndergaard HB, von Essen MR, Sellebjerg F. J Leukoc Biol. 2017 May;101(5):1211-1220.

The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis.

Bisgaard AK, Pihl-Jensen G, Frederiksen JL. Mult Scler Relat Disord. 2017 Nov;18:213-217. 

Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.

Blinkenberg M, Soelberg Sørensen P. CNS Drugs. 2017 May;31(5):357-371. 

Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.

Britze J, Pihl-Jensen G, Frederiksen JL. J Neurol. 2017 Sep;264(9):1837-1853. 

Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.

Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB. Cytokine. 2017 May;93:15-25. 

Evolving concepts in the treatment of relapsing multiple sclerosis.

Comi G, Radaelli M, Soelberg Sørensen P. Lancet. 2017 Apr 1;389(10076):1347-1356.

Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.

de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H; MAGNIMS study group and for neuGRID. Neuroimage. 2017 Dec;163:106-114. 

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. Eur J Neurol. 2017 Mar;24(3):516-522. 

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group. Ann Neurol. 2017 Jul;82(1):20-29. 

Vaccines and multiple sclerosis.

Frederiksen JL, Topsøe Mailand M. Acta Neurol Scand. 2017 Nov;136 Suppl 201:49-51.

Vaccines and multiple sclerosis: a systematic review.

Mailand MT, Frederiksen JL. J Neurol. 2017 Jun;264(6):1035-1050. 

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement.

Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, Sellebjerg F, Ullum H, Thørner LW, Gustavsen MW, Harbo HF, Obradovic D, Gianfrancesco MA, Barcellos LF, Schaefer CA, Hillert J, Kockum I, Olsson T, Alfredsson L. Eur J Epidemiol. 2017 Oct;32(10):909-919.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P. Mult Scler. 2017 Feb;23(2):234-241. 

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C. Front Neurol. 2017 Jul 6;8:305. 

Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.

Koch-Henriksen N, Laursen B, Stenager E, Magyari M. J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):626-631. 

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium. PLoS One. 2017 Feb 7;12(2):e0170395. 

Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.

Lundell H, Svolgaard O, Dogonowski AM, Romme Christensen J, Selleberg F, Soelberg Sørensen P, Blinkenberg M, Siebner HR, Garde E. Acta Neurol Scand. 2017 Oct;136(4):330-337.

Striving for balance between caring and restraint: young adults' experiences with parental multiple sclerosis.

Moberg JY, Larsen D, Brødsgaard A. J Clin Nurs. 2017 May;26(9-10):1363-1374. 

Employment, disability pension and income for children with parental multiple sclerosis.

Moberg JY, Laursen B, Koch-Henriksen N, Thygesen LC, Brødsgaard A, Soelberg Sørensen P, Magyari M. Mult Scler. 2017 Jul;23(8):1148-1156. 

Age at Menarche and Risk of Multiple Sclerosis: A Prospective Cohort Study Based on the Danish National Birth Cohort.

Nielsen NM, Harpsøe M, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Baker JL, Hjalgrim H, Frisch M, Bager P. Am J Epidemiol. 2017 Apr 15;185(8):712-719.

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Nielsen BR, Ratzer R, Börnsen L, von Essen MR, Christensen JR, Sellebjerg F. J Neuroimmunol. 2017 Sep 15;310:17-25. 

Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.

Nielsen NM, Munger KL, Koch-Henriksen N, Hougaard DM, Magyari M, Jørgensen KT, Lundqvist M, Simonsen J, Jess T, Cohen A, Stenager E, Ascherio A. Neurology. 2017 Jan 3;88(1):44-51. 

Bone microarchitecture and bone mineral density in multiple sclerosis.

Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS. Acta Neurol Scand. 2018 Mar;137(3):363-369. 

Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review.

Pihl-Jensen G, Schmidt MF, Frederiksen JL. Clin Neurophysiol. 2017 Jul;128(7):1234-1245.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P. Mult Scler. 2017 Apr;23(5):675-685. 

Defining active progressive multiple sclerosis.

Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J. Mult Scler. 2017 Nov;23(13):1727-1735.

Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study.

Singh A, Subhi Y, Krogh Nielsen M, Falk MK, Matzen SMH, Sellebjerg F, Sørensen TL. Sci Rep. 2017 Apr 4;7(1):605. 

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Int J MS Care. 2017 Jan-Feb;19(1):16-24.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB. Mult Scler Relat Disord. 2017 Apr;13:25-27.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M. Eur J Neurol. 2017 Jun;24(6):825-834. c

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M. Neurology. 2017 Oct 17;89(16):1668-1675. 

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB. Acta Neurol Scand. 2017 Jan;135(1):129-133. 

  2016

Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.

Degn M, Modvig S, Dyring-Andersen B, Bonefeld CM, Frederiksen JL, Geisler C, von Essen MR. Mult Scler. 2016 Jul;22(8):1013-20. 

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F. Mult Scler. 2016 Jun;22(7):926-34. 

Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.

Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, Frederiksen JL. Mult Scler. 2016 Apr;22(5):590-8. 

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4.

Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.

Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E, Ammitzbøll C, Larsen IU, Hjermind LE, Sellebjerg F, Nielsen JE. Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e287.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M. Mult Scler Relat Disord. 2016 Nov;10:181-186. 

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS. J Neurol. 2016 Dec;263(12):2484-2493. 

NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: cotsapas@broadinstitute.org; International Multiple Sclerosis Genetics Consortium. Neuron. 2016 Oct 19;92(2):333-335. 

Ozanimod: a better or just another S1P receptor modulator?

Sørensen PS. Lancet Neurol. 2016 Apr;15(4):345-7.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M. Ther Adv Neurol Disord. 2016 Jan;9(1):44-52.

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO.

Soelberg Sorensen P. Mult Scler. 2016 Sep;22(10):1260-3. 

Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.

Soelberg Sorensen P, Sellebjerg F. Mult Scler. 2016 Aug;22(9):1112-3. 

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators. Eur J Neurol. 2016 May;23(5):861-70. 

Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?

Sørensen PS. Nat Rev Neurol. 2016 Jan;12(1):5-6. 

Safety concerns and risk management of multiple sclerosis therapies.

Soelberg Sorensen P. Acta Neurol Scand. 2017 Sep;136(3):168-186.

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D. Ther Adv Neurol Disord. 2016 Jan;9(1):31-43.

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F. Mult Scler. 2016 Jun;22(7):926-34. 

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L. Mult Scler Relat Disord. 2016 Nov;10:66-72. 

Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.

Oturai DB, Søndergaard HB, Börnsen L, Sellebjerg F, Christensen JR. Scand J Immunol. 2016 Jan;83(1):72-80. 

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Mult Scler. 2016 Oct;22(11):1386-1396. 

The association between multiple sclerosis and uveitis.

Olsen TG, Frederiksen J. Surv Ophthalmol. 2017 Jan-Feb;62(1):89-95. 

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Neurology. 2016 Mar 8;86(10):920-30.

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191.

Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.

Nielsen NM, Harpsøe MC, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Frisch M, Bager P. Mult Scler. 2016 Oct;22(11):1444-1451. 

Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.

Nielsen CH, Börnsen L, Sellebjerg F, Brimnes MK. PLoS One. 2016 Jan 12;11(1):e0146971. 

Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis.

Møllgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Eur J Neurol. 2016 May;23(5):898-905.

Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.

Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, Frederiksen JL. Mult Scler. 2016 Apr;22(5):590-8. 

Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.

Moberg JY, Magyari M, Koch-Henriksen N, Thygesen LC, Laursen B, Soelberg Sørensen P. J Neurol. 2016 Nov;263(11):2229-2237. 

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Lancet Neurol. 2016 May;15(6):574-84.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS. Clin Epidemiol. 2016 Oct 25;8:549-552. 

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P. Mult Scler. 2016 Jun;22(7):944-54. 

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lancet. 2016 Mar 12;387(10023):1075-1084.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB. Mult Scler Relat Disord. 2016 Nov;10:169-173. 

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB. Neurology. 2016 Jan 5;86(1):88-93.

Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.

Lam MA, Maghzal GJ, Khademi M, Piehl F, Ratzer R, Romme Christensen J, Sellebjerg FT, Olsson T, Stocker R. Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. 

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium. J Immunol Methods. 2016 Mar;430:1-9. 

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. 

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB. Mult Scler Relat Disord. 2016 Sep;9:104-9.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Neurology. 2016 Nov 8;87(19):1985-1992.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF. Neurol Genet. 2016 Aug 4;2(4):e87. 

Human pegivirus detected in a patient with severe encephalitis using a metagenomic pan-virus array.

Fridholm H, Østergaard Sørensen L, Rosenstierne MW, Nielsen H, Sellebjerg F, Bengård Andersen Å, Fomsgaard A. J Clin Virol. 2016 Apr;77:5-8. 

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4. 

Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report.

Dalbjerg SM, Tsakiri A, Frederiksen JL. Mult Scler Relat Disord. 2016 Jul;8:93-5.

The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium. Neurology. 2016 Jun 14;86(24):2303-9. 

Zinc in Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Bredholt M, Frederiksen JL. ASN Neuro. 2016 Jun 9;8(3):1759091416651511.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium. PLoS One. 2016 Nov 2;11(11):e0162752. 

  2015

Multiple sclerosis: A clinically useful genetic variant in multiple sclerosis?

Sellebjerg F, Oturai AB. Nat Rev Neurol. 2015 Jul;11(7):371-2. 

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti CF. Ann Neurol. 2015 Nov;78(5):710-21. 

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium. Clin Exp Immunol. 2015 Sep;181(3):385-400.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G. Nat Genet. 2015 Jul;47(7):717-726. 

Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.

Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB. Mult Scler. 2015 Oct;21(12):1557-65. 

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F. PLoS One. 2015 Mar 4;10(3):e0118830. 

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G. Nat Genet. 2015 Oct;47(10):1107-1113. 

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Goris A, Pauwels I, Gustavsen MW, van Son B, Hilven K, Bos SD, Celius EG, Berg-Hansen P, Aarseth J, Myhr KM, D'Alfonso S, Barizzone N, Leone MA, Martinelli Boneschi F, Sorosina M, Liberatore G, Kockum I, Olsson T, Hillert J, Alfredsson L, Bedri SK, Hemmer B, Buck D, Berthele A, Knier B, Biberacher V, van Pesch V, Sindic C, Bang Oturai A, Søndergaard HB, Sellebjerg F, Jensen PE, Comabella M, Montalban X, Pérez-Boza J, Malhotra S, Lechner-Scott J, Broadley S, Slee M, Taylor B, Kermode AG, Gourraud PA; International Multiple Sclerosis Genetics Consortium, Sawcer SJ, Andreassen BK, Dubois B, Harbo HF. Brain. 2015 Mar;138(Pt 3):632-43. 

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M. Mult Scler. 2015 Mar;21(3):282-93.

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.

Modvig S, Degn M, Roed H, Sørensen TL, Larsson HB, Langkilde AR, Frederiksen JL, Sellebjerg F. Mult Scler. 2015 Dec;21(14):1761-70.

Registers of multiple sclerosis in Denmark.

Koch-Henriksen N, Magyari M, Laursen B. Acta Neurol Scand. 2015;132(199):4-10.

Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.

Laursen JH, Søndergaard HB, Albrechtsen A, Frikke-Schmidt R, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A. Mult Scler. 2015 Oct;21(11):1414-22.

Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort.

Westerlind H, Imrell K, Ramanujam R, Myhr KM, Celius EG, Harbo HF, Oturai AB, Hamsten A, Alfredsson L, Olsson T, Kockum I, Koski T, Hillert J. Eur J Hum Genet. 2015 May;23(5):688-92. 

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Penner IK, Sivertsdotter EC, Celius EG, Fuchs S, Schreiber K, Berkö S, Svenningsson A; TYNERGY trial investigators. Front Neurol. 2015 Feb 23;6:18. 

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J. Mult Scler. 2015 Mar;21(3):332-41. 

The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N. Mult Scler. 2015 Mar;21(3):305-17. 

The use of valproic acid and multiple sclerosis.

Nielsen NM, Svanström H, Stenager E, Magyari M, Koch-Henriksen N, Pasternak B, Hviid A. Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):262-8. 

  2014

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Mult Scler. 2014 Apr;20(5):577-87. 

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.

Møller M, Søndergaard HB, Koch-Henriksen N, Sorensen PS, Sellebjerg F, Oturai AB. Acta Neurol Scand. 2014 Jan;129(1):27-31. 

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS.

Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, Sellebjerg F, Sørensen PS, Helin K, Issazadeh-Navikas S. Nat Med. 2014 Mar;20(3):272-82. 

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.

Lyksborg M, Siebner HR, Sørensen PS, Blinkenberg M, Parker GJ, Dogonowski AM, Garde E, Larsen R, Dyrby TB. PLoS One. 2014 Apr 18;9(4):e95540. 

Myasthenia and risk of cancer: a population-based case-control study.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Eur J Neurol. 2014 May;21(5):773-8. 

Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Eur J Neurol. 2014 Mar;21(3):454-8.

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Romme Christensen J, Romme Nielsen B, Sørensen PS, Börnsen L, Sellebjerg F. J Neuroimmunol. 2014 Nov 15;276(1-2):195-201.

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.

Romme Christensen J, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F. Neurology. 2014 Apr 29;82(17):1499-507. 

Prediction of response to interferon therapy in multiple sclerosis.

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB. Acta Neurol Scand. 2014 Oct;130(4):268-75. 

New management algorithms in multiple sclerosis.

Sorensen PS. Curr Opin Neurol. 2014 Jun;27(3):246-59.

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. J Neurol. 2014 Jun;261(6):1170-7. 

Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort.

Westerlind H, Imrell K, Ramanujam R, Myhr KM, Celius EG, Harbo HF, Oturai AB, Hamsten A, Alfredsson L, Olsson T, Kockum I, Koski T, Hillert J. Eur J Hum Genet. 2015 May;23(5):688-92. 

Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis.

Wu X, Hanson LG, Skimminge A, Sorensen PS, Paulson OB, Mathiesen HK, Blinkenberg M. Neurol Res. 2014 Aug;36(8):701-8.

Onset symptoms in paediatric multiple sclerosis.

Boesen MS, Sellebjerg F, Blinkenberg M. Dan Med J. 2014 Apr;61(4):A4800.

CLIPPERS among patients diagnosed with non-specific CNS neuroinflammatory diseases.

Kerrn-Jespersen BM, Lindelof M, Illes Z, Blaabjerg M, Lund EL, Klausen C, Christiansen I, Sellebjerg F, Kondziella D. J Neurol Sci. 2014 Aug 15;343(1-2):224-7.

Clinical relevance of brain volume measures in multiple sclerosis.

De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, Sellebjerg F, Stankoff B, Walczak A, Wiendl H, Kieseier BC. CNS Drugs. 2014 Feb;28(2):147-56. 

Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes.

Enevold C, Kjær L, Nielsen CH, Voss A, Jacobsen RS, Hermansen ML, Redder L, Oturai AB, Jensen PE, Bendtzen K, Jacobsen S. Rheumatol Int. 2014 Oct;34(10):1401-8. 

Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general.

Gustavsen MW, Viken MK, Celius EG, Berge T, Mero IL, Berg-Hansen P, Aarseth JH, Myhr KM, Søndergaard HB, Sellebjerg F, Oturai AB, Hillert J, Alfredsson L, Olsson T, Kockum I, Lie BA, Harbo HF. J Neuroimmunol. 2014 Sep 15;274(1-2):174-9. 

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Mult Scler. 2014 Apr;20(5):577-87. 

Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.

Laursen JH, Søndergaard HB, Albrechtsen A, Frikke-Schmidt R, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A. Mult Scler. 2015 Oct;21(11):1414-22. 

  2013

Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).

Magyari M, Bach Søndergaard H, Sellebjerg F, Soelberg Sørensen P. Mult Scler Relat Disord. 2013 Apr;2(2):141-6. 

Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009.

Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Eur J Neurol. 2013 Feb;20(2):309-14. 

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.

Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F. Mult Scler. 2013 Jun;19(7):877-84.

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.

Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS. Mult Scler. 2013 Feb;19(2):179-87. 

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS. Mult Scler. 2013 Aug;19(9):1226-9.

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls.

International Multiple Sclerosis Genetics Consortium. Am J Hum Genet. 2013 Jun 6;92(6):854-65. 

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, McCauley JL. Nat Genet. 2013 Nov;45(11):1353-60. 

Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.

Lund H, Krakauer M, Skimminge A, Sellebjerg F, Garde E, Siebner HR, Paulson OB, Hesse D, Hanson LG. PLoS One. 2013;8(2):e56375. 

Reproduction and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS. Mult Scler. 2013 Oct;19(12):1604-9. 

Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Mero IL, Gustavsen MW, Sæther HS, Flåm ST, Berg-Hansen P, Søndergaard HB, Jensen PE, Berge T, Bjølgerud A, Muggerud A, Aarseth JH; International Multiple Sclerosis Genetics Consortium, Myhr KM, Celius EG, Sellebjerg F, Hillert J, Alfredsson L, Olsson T, Oturai AB, Kockum I, Lie BA, Andreassen BK, Harbo HF. PLoS One. 2013;8(3):e58352.

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.

Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D. Mult Scler. 2013 Oct;19(11):1533-8. 

Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Eur J Neurol. 2013 Jun;20(6):942-8. 

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Romme Christensen J, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. PLoS One. 2013;8(3):e57820.

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner IK; Tynergy Trial Investigators. PLoS One. 2013;8(3):e58643. 

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F. Mult Scler. 2013 Dec;19(14):1849-57.

Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Theibich A, Dreyer L, Magyari M, Locht H. Clin Rheumatol. 2014 May;33(5):719-23. 

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.

Mathiesen HK, Sorensen PS. Expert Rev Neurother. 2013 Dec;13(12):1309-17.

Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis.

Dogonowski AM, Siebner HR, Soelberg Sørensen P, Paulson OB, Dyrby TB, Blinkenberg M, Madsen KH. Acta Neurol Scand. 2013 Nov;128(5):328-35. 

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ. J Neurol. 2013 Apr;260(4):1136-46.

  2012

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.

Sellebjerg F, Hedegaard CJ, Krakauer M, Hesse D, Lund H, Nielsen CH, Søndergaard HB, Sørensen PS. Mult Scler. 2012 Mar;18(3):305-13. 

Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study.

Blinkenberg M, Mathiesen HK, Tscherning T, Jønsson A, Svarer C, Holm S, Sellebjerg F, Paulson OB, Hanson LG, Sorensen PS. Neurol Res. 2012 Jan;34(1):52-8. 

Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis.

Blinkenberg M, Akeson P, Sillesen H, Lövgaard S, Sellebjerg F, Paulson OB, Siebner HR, Sørensen PS. Acta Neurol Scand. 2012 Dec;126(6):421-7. 

Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans.

Brambilla P, Esposito F, Lindstrom E, Sorosina M, Giacalone G, Clarelli F, Rodegher M, Colombo B, Moiola L, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, Celius EG, Galimberti D, Sørensen PS, Martinelli V, Oturai AB, Harbo HF, Hillert J, Comi G, Martinelli-Boneschi F. Neurosci Lett. 2012 Nov 21;530(2):155-60.

Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma.

Braendstrup P, Langkilde AR, Schreiber K, Ravnborg M, Sellebjerg F, Vindeløv L. Case Rep Neurol. 2012 May;4(2):101-6. 

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Börnsen L, Christensen JR, Ratzer R, Oturai AB, Sørensen PS, Søndergaard HB, Sellebjerg F. PLoS One. 2012;7(11):e47578.

Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis.

Dogonowski AM, Siebner HR, Sørensen PS, Wu X, Biswal B, Paulson OB, Dyrby TB, Skimminge A, Blinkenberg M, Madsen KH. Mult Scler. 2013 Apr;19(5):559-66.

Prediction of antibody persistency from antibody titres to natalizumab.

Jensen PE, Koch-Henriksen N, Sellebjerg F, Sørensen PS. Mult Scler. 2012 Oct;18(10):1493-9. 

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS. Eur J Neurol. 2012 Oct;19(10):1311-7.

A genome-wide association study in progressive multiple sclerosis.

Martinelli-Boneschi F, Esposito F, Brambilla P, Lindström E, Lavorgna G, Stankovich J, Rodegher M, Capra R, Ghezzi A, Coniglio G, Colombo B, Sorosina M, Martinelli V, Booth D, Oturai AB, Stewart G, Harbo HF, Kilpatrick TJ, Hillert J, Rubio JP, Abderrahim H, Wojcik J, Comi G. Mult Scler. 2012 Oct;18(10):1384-94. 

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Romme Christensen J, Börnsen L, Hesse D, Krakauer M, Sørensen PS, Søndergaard HB, Sellebjerg F. J Neuroinflammation. 2012 Sep 14;9:215. 

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Sellebjerg F, Krakauer M, Limborg S, Hesse D, Lund H, Langkilde A, Søndergaard HB, Sørensen PS. PLoS One. 2012;7(6):e35927.

FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Sellebjerg F, Krakauer M, Khademi M, Olsson T, Sørensen PS. Clin Exp Immunol. 2012 Nov;170(2):149-55. 

Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.

Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group. Clin Drug Investig. 2012 Jan 1;32(1):15-27. 

Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.

Sørensen PS. Mult Scler. 2012 Feb;18(2):131-2. 

Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS.

Tümer Z, Bertelsen B, Gredal O, Magyari M, Nielsen KC, Lucamp, Grønskov K, Brøndum-Nielsen K. Neurobiol Aging. 2012 Jan;33(1):208.e1-5. 

  2011

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Compston A. Nature. 2011 Aug 10;476(7359):214-9. 

The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1.

Nexø BA, Christensen T, Frederiksen J, Møller-Larsen A, Oturai AB, Villesen P, Hansen B, Nissen KK, Laska MJ, Petersen TS, Bonnesen S, Hedemand A, Wu T, Wang X, Zhang X, Brudek T, Maric R, Søndergaard HB, Sellebjerg F, Brusgaard K, Kjeldbjerg AL, Rasmussen HB, Nielsen AL, Nyegaard M, Petersen T, Børglum AD, Pedersen FS. PLoS One. 2011 Feb 2;6(2):e16652. 

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R. Mult Scler. 2011 Sep;17(9):1074-8.

Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.

Sørensen PS, Koch-Henriksen N, Jensen PE. Neurology. 2011 Feb 22;76(8):759-60. 

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators. Lancet Neurol. 2011 Aug;10(8):691-701. 

Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655.

Søndergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Lindén M, Mero IL, Myhr KM, Celius EG, Harbo HF, Christensen JR, Börnsen L, Sørensen PS, Oturai AB. Eur J Hum Genet. 2011 Oct;19(10):1100-3. 

Identifying patients with myasthenia for epidemiological research by linkage of automated registers.

Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Neuroepidemiology. 2011;37(2):120-8. 

Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.

Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH. Mult Scler. 2011 May;17(5):567-77. 

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Sørensen PS, Sellebjerg F. Eur J Neurol. 2011 Feb;18(2):266-72. 

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.

Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. Mult Scler. 2011 Jan;17(1):32-42. 

Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis.

Hedegaard CJ, Enevold C, Sellebjerg F, Bendtzen K, Nielsen CH. PLoS One. 2011;6(5):e20253. 

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Sørensen PS, Sellebjerg F. Eur J Neurol. 2011 Feb;18(2):266-72. 

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T. Mult Scler. 2011 Mar;17(3):335-43.

The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.

International Multiple Sclerosis Genetics Consortium. PLoS One. 2011 Apr 28;6(4):e18813. 

  2010

Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis.

Ockinger J, Stridh P, Beyeen AD, Lundmark F, Seddighzadeh M, Oturai A, Sørensen PS, Lorentzen AR, Celius EG, Leppä V, Koivisto K, Tienari PJ, Alfredsson L, Padyukov L, Hillert J, Kockum I, Jagodic M, Olsson T. Genes Immun. 2010 Mar;11(2):142-54

Demyelination versus remyelination in progressive multiple sclerosis.

Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H. Brain. 2010 Oct;133(10):2983-98. 

A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis.

Mero IL, Lorentzen AR, Ban M, Smestad C, Celius EG, Aarseth JH, Myhr KM, Link J, Hillert J, Olsson T, Kockum I, Masterman T, Oturai AB, Søndergaard HB, Sellebjerg F, Saarela J, Kemppinen A, Elovaara I, Spurkland A, Dudbridge F, Lie BA, Harbo HF. Eur J Hum Genet. 2010 Apr;18(4):502-4

The changing demographic pattern of multiple sclerosis epidemiology.

Koch-Henriksen N, Sørensen PS. Lancet Neurol. 2010 May;9(5):520-32

Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L. Am J Hum Genet. 2010 Feb 12;86(2):285-91

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.

International Multiple Sclerosis Genetics Conssortium (IMSGC). Genes Immun. 2010 Jul;11(5):397-405

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.

Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F. Neurology. 2010 May 4;74(18):1455-62

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.

Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Mult Scler. 2010 Aug;16(8):942-9. 

RGMA and IL21R show association with experimental inflammation and multiple sclerosis.

Nohra R, Beyeen AD, Guo JP, Khademi M, Sundqvist E, Hedreul MT, Sellebjerg F, Smestad C, Oturai AB, Harbo HF, Wallström E, Hillert J, Alfredsson L, Kockum I, Jagodic M, Lorentzen J, Olsson T. Genes Immun. 2010 Jun;11(4):279-93.